{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:46:50Z","timestamp":1783684010020,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcyt.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:27:06Z","timestamp":1681226826000},"page":"763-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-6090","authenticated-orcid":false,"given":"Maria","family":"Karvouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-0876","authenticated-orcid":false,"given":"Marcos","family":"Vidal-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-0748","authenticated-orcid":false,"given":"Katharina H.","family":"Susek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alamdar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8105-5721","authenticated-orcid":false,"given":"Mari","family":"Gilljam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dixon","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-7387","authenticated-orcid":false,"given":"Hans-Gustaf","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnika K.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Alici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27-28","key":"10.1016\/j.jcyt.2023.03.006_bib0001","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.006_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jcyt.2023.03.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"Suppl 12","key":"10.1016\/j.jcyt.2023.03.006_bib0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jcyt.2023.03.006_bib0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jcyt.2023.03.006_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jcyt.2023.03.006_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121527","article-title":"CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jcyt.2023.03.006_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cyto.b.21092","article-title":"CD38 and CD157: a long journey from activation markers to multifunctional molecules","volume":"84","author":"Quarona","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.jcyt.2023.03.006_bib0009","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.006_bib0010","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2005-07-2913","article-title":"CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells","volume":"107","author":"Frasca","year":"2006","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.jcyt.2023.03.006_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11010-011-0765-x","article-title":"Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR","volume":"352","author":"Ohta","year":"2011","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0012","article-title":"Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer","volume":"4","author":"Crowell","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0013","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jaci.2004.04.040","article-title":"Methodologic advancements in the study of airway smooth muscle","volume":"114","author":"Kotlikoff","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2023.03.006_bib0014","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/j.1582-4934.2011.01462.x","article-title":"Implication of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis","volume":"16","author":"Boini","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.jcyt.2023.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V77.5.1071.1071","article-title":"Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody","volume":"77","author":"Stevenson","year":"1991","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.006_bib0016","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.jcyt.2023.03.006_bib0017","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jcyt.2023.03.006_bib0018","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.006_bib0019","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10192","key":"10.1016\/j.jcyt.2023.03.006_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.13426","article-title":"Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment","volume":"105","author":"Afram","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2023.03.006_bib0022","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.006_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.jcyt.2023.03.006_bib0024","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jcyt.2023.03.006_bib0025","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.jcyt.2023.03.006_bib0026","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.jcyt.2023.03.006_bib0027","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"10.1016\/j.jcyt.2023.03.006_bib0028","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"5562","key":"10.1016\/j.jcyt.2023.03.006_bib0029","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0030","article-title":"Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma","volume":"3","author":"Nahi","year":"2022","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.006_bib0031","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0032","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-shelf CAR-NK cells for cancer immunotherapy","volume":"23","author":"Siegler","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0033","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jcyt.2023.03.006_bib0034","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/HS9.0000000000000596","article-title":"CD38-specific chimeric antigen receptor expressing natural killer KHYG-1 cells: a proof of concept for an \"off the shelf\" therapy for multiple myeloma","volume":"5","author":"Stikvoort","year":"2021","journal-title":"Hemasphere"},{"issue":"15","key":"10.1016\/j.jcyt.2023.03.006_bib0035","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","article-title":"Fc\u03b5RI\u03b3-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma","volume":"5","author":"Bigley","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.jcyt.2023.03.006_bib0036","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2023.03.006_bib0037","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.006_bib0038","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2007-09-110312","article-title":"Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components","volume":"111","author":"Alici","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0039","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/gt.2009.134","article-title":"A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration","volume":"17","author":"Loew","year":"2010","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.006_bib0040","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"issue":"W1","key":"10.1016\/j.jcyt.2023.03.006_bib0041","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.jcyt.2023.03.006_bib0042","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)","volume":"49","author":"Cossarizza","year":"2019","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0043","first-page":"181","article-title":"Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs","volume":"14","author":"Brunner","year":"1968","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.006_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.006_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jcyt.2023.03.006_bib0046","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jcyt.2023.03.006_bib0047","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jcyt.2023.03.006_bib0048","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jcyt.2023.03.006_bib0049","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.006_bib0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD(+)axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcyt.2023.03.006_bib0051","article-title":"CD38 contributes to human natural killer cell responses through a role in immune synapse formation","author":"Mathieu Le Gars","year":"2019","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.jcyt.2023.03.006_bib0052","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem J"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:48:09Z","timestamp":1761443289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1465324923000683"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.006","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}